139.71 USD
+0.81 (+0.58%)
AT CLOSE (11:59 AM EDT)
Gilead Sciences Inc (GILD)
NASDAQ: GILD • USD
140.42
+0.71 (+0.51%)
POST MARKET (AS OF 07:58 PM EDT)
Market: CLOSED
Open?$139.61
High?$141.34
Low?$138.64
Prev. Close?$139.71
Volume?4.9M
Avg. Volume?6.6M
VWAP?$139.64
Rel. Volume?0.75x
Bid / Ask
Bid?$137.25 × 100
Ask?$141.10 × 100
Spread?$3.85
Midpoint?$139.18
Valuation & Ratios
Market Cap?173.4B
Shares Out?1.2B
Float?1.2B
Float %?99.7%
P/E Ratio?20.38
P/B Ratio?7.64
EPS?$6.86
Dividend?2.31%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.55Adequate
Quick Ratio?1.40Adequate
Cash Ratio?0.64Adequate
Debt/Equity?1.10Moderate
ValuationFAIRLY VALUED
Score67/100
P/E?20.4FAIR▾
P/B?7.64FAIR▾
P/S?5.89FAIR▾
P/FCF?18.3CHEAP▾
EV/EBITDA?13.3FAIR▾
EV/Sales?6.48HIGH▾
Returns & Efficiency
ROE?37.5%STRONG▾
ROA?14.4%STRONG▾
Cash Flow & Enterprise
FCF?$9.5B
Enterprise Value?$190.8B
Related Companies
Loading...
News
Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees
17.0K
Market Cap
173.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1992-01-22
Address
333 LAKESIDE DR
FOSTER CITY, CA 94404
Phone: (650) 574-3000
FOSTER CITY, CA 94404
Phone: (650) 574-3000